Marketing Communication
CYBO
Bionic ETF
VanEck Medical Robotics and Bionic Engineering UCITS ETF
Marketing Communication
CYBO
Bionic ETF
VanEck Medical Robotics and Bionic Engineering UCITS ETF
ISIN:
IE0005TF96I9
WKN:
A3DT2R
Fund Description
As the global population ages, so does the demand for biologically-inspired systems that improve the quality of later life1. VanEck’s Medical Robotics and Bionic Engineering ETF tracks the performance of the portfolio of innovative companies that operate in medical technology – spanning medical robotics, bioprinting, advanced implants prosthesis, and organ and tissue preservation.
-
NAV$20.51
as of 06 Feb 2026 -
YTD RETURNS-1.37%
as of 06 Feb 2026 -
Total Net Assets$11.3 million
as of 06 Feb 2026 -
Total Expense Ratio0.55%
-
Inception Date02 Dec 2022
-
SFDR ClassificationArticle 8
Overview
Fund Description
As the global population ages, so does the demand for biologically-inspired systems that improve the quality of later life1. VanEck’s Medical Robotics and Bionic Engineering ETF tracks the performance of the portfolio of innovative companies that operate in medical technology – spanning medical robotics, bioprinting, advanced implants prosthesis, and organ and tissue preservation. The Fund has a sustainable investment objective, with an emphasis on social objectives:
- Invest in companies at the forefront of improving quality of life for the world’s ageing population
- Gain diversified exposure to companies involved in medical robotics implants and bionic enhancements for chronic diseases and functional impairments
- Access companies earning at least half their revenues from medical robotics and bionic engineering-related industries
- Invest in an ETF that screens out companies that violate social norms, derive revenues from controversial weapons, or participate in fossil fuel sectors, nuclear power, civilian firearms or tobacco
1Source: McKinsey & Company. McKinsey Technology Trends Outlook 2025. July 2025.
Main Risk Factors: Equity market risk, industry or sector concentration risk, Liquidity Risks. Investors must consider all the fund's characteristics or objectives as detailed in the prospectus or related documents before making an investment decision. Please refer to the sustainability-related disclosures in the document section, to the
and the Prospectus for other important information before investing.
Underlying Index
MVIS® Global Bionic Healthcare ESG Index (MVBIONTR)
Fund Highlights
- Invest in companies at the forefront of improving quality of life for the world’s ageing population
- Gain diversified exposure to companies involved in medical implants and bionic enhancements for chronic diseases and functional impairments
- Access companies earning at least half their revenues from bionic engineering-related industries
- Invest in an ETF that screens out companies that violate social norms, derive revenues from controversial weapons, or participate in fossil fuel sectors, nuclear power, civilian firearms or tobacco
Risk Factors: Equity market risk, industry or sector concentration risk, Liquidity Risks. Investors must consider all the fund's characteristics or objectives as detailed in the prospectus or related documents before making an investment decision. Please refer to the sustainability-related disclosures in the document section, to the
and the Prospectus for other important information before investing.
Underlying Index
MVIS® Global Bionic Healthcare ESG Index (MVBIONTR)
Capital Markets
VanEck partners with esteemed market makers to ensure the availability of our products for trading on the mentioned stock exchanges. Our Capital Markets team is committed to continuously monitoring and assessing spreads, sizes, and prices to ensure optimal trading conditions for our clients. Furthermore, VanEck ETFs are available on various trading platforms, and we collaborate with a wider range of reputable Authorized Participants (APs) to promote an efficient and fair trading environment. For more information about our APs and to contact our Capital Markets team, please visit factsheet capital markets.pdfPerformance
Holdings
Portfolio
Documents
Index
Index Description
The MVIS Global Bionic Healthcare ESG Index is a global index that tracks the performance of the largest and most liquid companies in medical/dental or vision-related implants, bioprinting, prosthesis, and medical robotics.
Index Key Points
Underlying Index
MVIS® Global Bionic Healthcare ESG Index (MVBIONTR)
The Index Composition:
The MVIS®Global Bionic Healthcare ESG Index (MVBIONTR) tracks the performance of the largest and most liquid companies in medical/dental or vision-related implants, bioprinting, prosthesis, and medical robotics. MVBION covers at least 90% of the investable universe.
Companies initially eligible for inclusion in Index:
- Companies involved in medical robotics and bionic healthcare industries. This includes companies with at least 50% (25% forcurrent components) of their revenues from the following sub-themes:
Medical, dental or vision-related implants, bioprinting, prosthesis, or preservation of organs and tissue, and/or medical robotics. The index does not include companies involved in implantable or wearable devices or materials used only for cosmetic purposes - Companies with at least 50% of their revenues from sectors defined above
- Market capitalization greater than $150 million
- Three-month average daily turnover greater than $1 million
- Minimum trading volume of 250,000 shares each month over last 6 months
- Company weightings are capped at 10%.
Index provider:
Awards
Main Risks
Main Risk Factors of a Medical Robotics ETF
The Fund’s assets may be concentrated in one or more particular sectors or industries. The Fund may be subject to the risk that economic, political or other conditions that have a negative effect on the relevant sectors or industries will negatively impact the Fund's performance to a greater extent than if the Fund’s assets were invested in a wider variety of sectors or industries.
The prices of the securities in the Fund are subject to the risks associated with investing in the securities market, including general economic conditions and sudden and unpredictable drops in value. An investment in the Fund may lose money.
Exists when a particular financial instrument is difficult to purchase or sell. If the relevant market is illiquid, it may not be possible to initiate a transaction or liquidate a position at an advantageous or reasonable price, or at all.